NASDAQ:IDXX
Related posts
Nervous markets await NvidiaThis summary was created by AI, based on 1 opinions in the last 12 months.
IDEXX Laboratories, represented by the ticker IDXX-Q, has faced scrutiny from experts primarily due to its inconsistency in performance. Many analysts have highlighted that the company's results and growth metrics fluctuate quite significantly, leading to concerns regarding its reliability in achieving projected targets. This inconsistency has cast a shadow over the company's credibility among investors, making it harder for them to gauge its future potential accurately. While IDEXX Laboratories continues to innovate and expand its product offerings, the lack of stability in performance metrics remains a crucial area for improvement. Overall, a more consistent performance trajectory could help restore investor confidence and attract new capital to propel growth.
IDEXX Laboratories is a American stock, trading under the symbol IDXX-Q on the NASDAQ (IDXX). It is usually referred to as NASDAQ:IDXX or IDXX-Q
In the last year, 3 stock analysts published opinions about IDXX-Q. 2 analysts recommended to BUY the stock. 1 analyst recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for IDEXX Laboratories.
IDEXX Laboratories was never recommended as a Top Pick on Stockchase. Read the latest stock experts ratings for IDEXX Laboratories.
Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.
3 stock analysts on Stockchase covered IDEXX Laboratories In the last year. It is a trending stock that is worth watching.
On 2025-08-22, IDEXX Laboratories (IDXX-Q) stock closed at a price of $645.61.
IDXX recently reported solid numbers as its topline growth accelerated to around 15% compared to previous quarters of around mid-to-high single digits. The company reacted favourably to the news as its share price jumped more than 20% in a single day. We think IDXX’s investment thesis as a high-quality, capital-light compounder in the pet healthcare industry remains intact. That being said, IDXX is now trading at around 50x Forward P/E, and growth over the next few years is expected to be around 8%-9%. We are comfortable holding the position here, but we don’t think it is too attractive to add at the current levels. We would prefer to be patient and wait for another opportunity to add to the name.
Unlock Premium - Try 5i Free